Please wait while the formulary information is being retrieved.
PARSABIV (ETELCALCETIDE HYDROCHLORIDE)
- Hyperparathyroidism secondary to CRF with dialysis
5 mg/mL intravenous solution
- Inject 0.5 milliliter (2.5 mg) by intravenous route 3 times per week at the end of dialysis after rinse back
Hyperparathyroidism secondary to CRF with dialysis
- Inject 1 milliliter (5 mg) by intravenous route 3 times per week at the end of dialysis after rinse back
- Inject 1 milliliter (5 mg) via venous line of dialysis circuit by intravenous route 3 times per week at the end of dialysis during rinse back
- Inject 2 milliliters (10 mg) via venous line of dialysis circuit by intravenous route 3 times per week at the end of dialysis during rinse back
- Inject 2 milliliters (10 mg) by intravenous route 3 times per week atthe end of dialysis after rinse back
- Inject 3 milliliters (15 mg) by intravenous route 3 times per week atthe end of dialysis after rinse back
- Inject 3 milliliters (15 mg) via venous line of dialysis circuit by intravenous route 3 times per week at the end of dialysis during rinse back
- Inject 0.5 milliliter (2.5 mg) via venous line of dialysis circuit byintravenous route 3 times per week at the end of dialysis during rinse back
- Inject 0.5 milliliter (2.5 mg) by intravenous route 3 times per week at the end of dialysis after rinse back
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Congenital long QT syndrome
- Gastrointestinal hemorrhage
- Hypocalcemia
Severe
Moderate
- Chronic heart failure
- Lower seizure threshold
- Seizure disorder
PARSABIV (ETELCALCETIDE HYDROCHLORIDE)
- Hyperparathyroidism secondary to CRF with dialysis
- Hypocalcemia
- Diarrhea
- Headache disorder
- Muscle spasm
- Nausea
- Paresthesia
- Vomiting
More Frequent
Severe
Less Severe
- Hypophosphatemia
- Hypotension
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adynamic bone disease
- Chronic heart failure
- Hyperkalemia
- Prolonged QT interval
- Upper GI bleed
- Urticaria
Less Severe
- Facial edema
- Myalgias
- Pruritus of skin
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Etelcalcetide
No pediatric safety and efficacy.
- 1 Day – 18 Years
- No pediatric safety and efficacy.
Etelcalcetide
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug dev tox; consider risk/benefit
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Etelcalcetide
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Hyperparathyroidism secondary to CRF with dialysis | |
| N25.81 | Secondary hyperparathyroidism of renal origin |
| 0-9 | A-Z |
|---|---|
| N25.81 | Secondary hyperparathyroidism of renal origin |
Formulary Reference Tool